The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Open accessPublished version of a preprint
Abstract
Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I study of regionally delivered, autologous, mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy. Intrapleural administration of 0.3M to 60M CAR T cells/kg in 27 patients (25 with MPM) was safe and well tolerated. CAR T cells were detected in peripheral blood for >100 days in 39% of patients. Following our demonstration that PD-1 blockade enhances CAR T-cell function in mice, 18 patients with MPM also received pembrolizumab safely. Among those patients, median overall survival from CAR T-cell infusion was 23.9 months (1-year overall survival, 83%). Stable disease was sustained for ≥6 months in 8 patients; 2 exhibited complete metabolic response on PET scan. Combination immunotherapy with CAR T cells and PD-1 blockade agents should be further evaluated in patients with solid tumors. Significance: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is feasible, safe, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors. See related commentary by Aldea et al., p. 2674. This article is highlighted in the In This Issue feature, p. 2659
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The results of phase 1 study demonstrated CAR-T cell therapy combined with α-PD-1/PD-L1 had confirmed antitumor activity in patients with malignant pleural diseases [344].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [344]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Self-citationInducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,098
Self-citationHuman T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J. F., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,062
Self-citationZalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Self-citationCombination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
Self-citation
Cited by
Sorted by citations
Items 401–500 of 599
Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Solid Tumors
Esmaeilzadeh, A., Jafari, D., Elahi, R., Bazargan, M., Rafie, M. Z., & Mansourabadi, A. H. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_156 · Cited by 4
Arming T cells to infiltrate pancreatic tumours
Cherkassky, L., & Adusumilli, P. S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00821-x · Cited by 4
Self-citationZahiu, T., Mihu, C. M., Boşca, A. B., Mărginean, M. V., Mocan, L. P., Lupean, R.-A., Suflețel, R. T., Mihu, C., & Melincovici, C. S. (2025) · Diagnostics · doi:10.3390/diagnostics15111323 · Cited by 4
Zhang, Z., Fu, D., & Cao, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2530288 · Cited by 3
SOX9: a novel janus-faced regulator in immunity and its promise as a therapeutic target
Shi, Q., & He, S. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1700812 · Cited by 3
CAR-T cell exhaustion in B cell lymphoma: Current status, mechanisms, and potential solutions
Zhao, R., Xia, J., Zheng, Y., Huang, W., Yu, L., & Wang, L. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201099 · Cited by 3
Mesothelin-expressing triple-negative breast cancer: a highly invasive and immunosuppressive subtype
Zhao, Z., Lei, H., Wang, B., Guo, L., Gao, L., Wang, B., Zheng, S., & Ying, J. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07860-x · Cited by 3
Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma
Grant, C. R., Bazhenova, L. A., & Yun, K. M. (2025) · Cancers · doi:10.3390/cancers17233863 · Cited by 3
Chen, H., Zhang, J., Huang, J., Wu, Z., Tang, L., Tian, Y., Gao, S., Huang, S., Cao, J., Chen, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07470-7 · Cited by 3
CAR-T therapy: Advances in respiratory diseases
Han, H., & Hu, Y. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.11.001 · Cited by 3
Carbone, M., Amos, C. I., Attanoos, R. L., Boeri, M., Bueno, R., Bunn, P. A., Chirieac, L. R., Cooper, B. T., Fennell, D. A., Galateau-Sallé, F., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.11.002 · Cited by 4
Self-citationAdvancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
Santos, G. N. D. S., DeJohn, C. R., Hess, S. M., Zsíros, E., & McGray, A. R. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013285 · Cited by 3
Wu, L., Rizaev, J., Fawy, K. F., Kadham, M. J., Dildora, N., Kurbanova, S., Atamuratova, Z., Dauletbaev, A., Lakshmaiya, N., & Al-Aouadi, R. F. A. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04175-7 · Cited by 3
Mesothelin biology and the evolving landscape of targeted immunotherapy
Boisgard, R., Chames, P., & Kerfélec, B. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201148 · Cited by 3
Lan, F., Song, J., Chen, X., & (9093), Y. Z. (2026) · Molecular Immunology · doi:10.1016/j.molimm.2026.02.011 · Cited by 3
CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30+ lymphomas
Yu, M., Liu, L., Zhou, X., Zhou, Y., Xu, S., Kong, F., Qi, L., Wu, J., Zhang, T., & Li, F. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07967-9 · Cited by 3
Overcoming stromal resistance in solid tumors with MMP2-engineered CAR-T cells
Tu, J., Zhu, Y., Li, X., Li, S., Zhang, G., He, Y., Lu, Z., & Zhang, C. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108163 · Cited by 3
Engineering BiTE-inspired IPSC-exosomes to potentiate CAR-T cell therapy against lung cancer
Wang, R., Fu, G., Dou, H., Hu, M., Li, Z., Gan, J., He, J., Li, X., Zhang, G., Li, X., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04242-3 · Cited by 3
Li, A., Wang, Y. Y., Bai, H., Xie, X., Xu, B., Wang, Y., Luo, S., Zhang, L., Zhao, Q., Duan, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73287-7 · Cited by 3
Self-citationSharma, S. R. K., Saha, S., Arora, S., Ahlawa, Y. K., Sheoran, S., Mukherjee, S., Sinha, A., Chaudhary, K., & Gosipatala, S. B. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100012 · Cited by 3
Challenges and recent advances in CAR-T cell therapy for solid tumors
Guo, Z., Zhong, D., Jiao, D., Wu, J., Wang, J., Lin, D., Fang, Y., & Wei, Y. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105434 · Cited by 3
Positron emission tomography probes for stem cell monitoring: a review
Xu, L. (2024) · American Journal of Translational Research · doi:10.62347/ciut6327 · Cited by 3
Galvagno, F., Leuci, V., Massa, A., Donini, C., Rotolo, R., Capellero, S., Proment, A., Vitali, L., Lombardi, A. M., Tuninetti, V., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03860-w · Cited by 3
Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival
Zhang, L., & Huang, M. (2025) · MedComm · doi:10.1002/mco2.70327 · Cited by 3
Maggadottir, S. M., Kvalheim, G., Wernhoff, P., Sæbøe‐Larssen, S., Revheim, M.-E. R., Josefsen, D., Wälchli, S., Helland, Å., & Inderberg, E. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1031232 · Cited by 4
Targeted Therapy in Mesotheliomas: Uphill All the Way
Bertoli, E., Carlo, E. D., Bortolot, M., Stanzione, B., Conte, A. D., Spina, M., & Bearz, A. (2024) · Cancers · doi:10.3390/cancers16111971 · Cited by 3
Tang, L., Sun, Q., Li, M., Yu, X., Meng, J., Zhang, Y., Ma, Y., Zeng, A., Li, Z., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1400177 · Cited by 3
Resuli, B., & Kauffmann-Guerrero, D. E. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001106 · Cited by 3
Tumor-Infiltrating Lymphocytes, CAR-, and T-Cell Receptor-Modified T Cells in Solid Cancer Oncology
Echchannaoui, H., Legscha, K. J., & Theobald, M. (2025) · Oncology Research and Treatment · doi:10.1159/000543998 · Cited by 2
CAR-T therapy for neuroendocrine neoplasms: a review of molecular targets and clinical translation
Golounina, O. O., Minniakhmetov, I. R., Khusainova, R. I., Loguinova, M. Y., Ринатович, С. Р., Fan, H., & Mokrysheva, N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1695716 · Cited by 2
Adoptive T‐cell therapies in the clinic
Shaha, S., Lourenco, L., Zhao, Z., & Mitragotri, S. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70086 · Cited by 2
Targeting the Dynamics Between TAMs and CAR‐T Cells in Solid Tumor Therapies
Zhang, X., Zheng, H., Liu, Z.-C., Luo, L., Dong, X., Cui, X., Wu, Y., & Chen, L. (2025) · Advanced Science · doi:10.1002/advs.202515700 · Cited by 3
Biological Rationale and Advantages of Image-Guided Immunotherapy
Cooper, M. E., & Sheth, R. A. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.09.009 · Cited by 2
CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancer
Kumar, R., Veillard, I. E., Xu, M., Al-Alem, L., Rueda, B. R., & Yeku, O. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1651526 · Cited by 2
Delsignore, M., Cassinari, G., Revello, S., Cerbone, L., Grosso, F., Arsura, M., & Porta, C. (2025) · Cancers · doi:10.3390/cancers17244020 · Cited by 2
Wu, S.-Y., Tyagi, A., Wu, K., Smith, E. C., Song, Q., Sharma, S., Miller, L. D., Zhang, W., Pan, B., Lin, H., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01613-x · Cited by 3
Mao, L., Ding, L., & Ding, Y. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04313-9 · Cited by 3
Zhang, K., Li, Z., O’Dair, M. K., Qu, D., Mealy, A., Nguyen, D., Cheng, H., Huang, D., Gopalakrishnan, S., Roberts, Z. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71904-z · Cited by 2
Harnessing the immune system: future directions in cancer immunotherapy
Zhang, J., & Cui, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1777816 · Cited by 2
Liu, K., Pham, V. T., Fu, S., Sun, L., & Huang, G. (2026) · Hematological Oncology · doi:10.1002/hon.70209 · Cited by 2
Chen, T.-W., Yu, S., Lu, S.-L., Yeh, C.-H., & Li, P. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01270-x · Cited by 2
CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions
Bach, D., Hoang, V. H., Pham, T. V., Huong, & Nguyen, D. D. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04425-w · Cited by 2
CAR-NK/CAR-T Cells: Emerging Immunotherapy of Cancer
Elemam, N. M., Youness, R. A., Abdelhamid, A. M., & Talaat, I. M. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_429 · Cited by 2
Malignant Pleural Mesothelioma: Analysis of 70 Cases in the Last Decade
García-Prieto, F., Pardo, S. C., Ramírez, M. T. R., & Fernández, A. A. (2024) · Open Respiratory Archives · doi:10.1016/j.opresp.2024.100326 · Cited by 2
Advances in CAR-T Cell Therapy for Solid Tumors
Li, Y., Zuo, B., Xing, Y., Zhang, R., Jia, L., Yan, B., Yang, A., & Yin, H. (2025) · Immune discovery. · doi:10.70322/immune.2025.10006 · Cited by 2
Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells
Osaki, M., Terakura, S., Hirano, S., Iwasa, T., Hatanaka, K. C., Hatanaka, Y., Sunagawa, M., Kokuryo, T., Adachi, Y., Takeuchi, Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009825 · Cited by 2
CAR T cells show promise in mesothelioma
Killock, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00547-4 · Cited by 2
Byun, A. J., Grosser, R., Choe, J. K., Rizk, N. P., Tang, L. H., Molena, D., Tan, K. S., Restle, D. J., Cheema, W., Zhu, A., et al. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005885 · Cited by 2
Self-citationDéveloppement des CAR-T cells dans les tumeurs solides
El-Ghazzi, N., Italiano, A., Bay, J., & Dougé, A. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.12.001 · Cited by 2
Offin, M. D., Fitzgerald, B. G., Zauderer, M. G., & Doroshow, D. B. (2023) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.140 · Cited by 1
Self-citationKim, J., & Lee, H. (2025) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2025.35.1.1 · Cited by 1
Concept CARs are picking up speed
Mansilla‐Soto, J., & Milone, M. C. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.008 · Cited by 1
Shi, D., Yan, X., Liu, J., Chen, H., Wang, X., Li, R., Tian, X., Lin, X., & Wang, Y. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108849 · Cited by 1
Self-citationZhan, J., Ho, M., Esser, L., Maslanka, C., Pastan, I., & Xia, D. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf028 · Cited by 1
Xu, C., Wu, J., Liu, W., Zhou, X., Liang, Q., Li, G., Wang, Y., Liu, Y., Cai, Q., Tang, Z., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664289 · Cited by 1
Immunotherapy advances in pleural mesothelioma
Zhang, A. L., & Hsu, M. L. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261420028 · Cited by 1
Pleural Mesothelioma: Current Therapeutic Strategies and Future Directions
Tang, H., Lu, X., Wu, S., Lu, G., Wen, J., Wei, M. Q., Sha, X., & Zhang, Z. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01755-w · Cited by 1
Hoang, T. A., Khan, S. M., & Sacher, A. (2026) · The Oncologist · doi:10.1093/oncolo/oyaf431 · Cited by 1
From biology to therapy: current standards and emerging strategies in pleural mesothelioma
van Genugten, J. H. L. T., de Gooijer, C. J., & Baas, P. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1778121 · Cited by 1
Xia, Y., Wang, M., Huang, T., Sun, K., & Wang, P. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1910011 · Cited by 1
Mai, Y., Wang, Z., Wang, J., Song, M., Xiang, T., He, Y., Chang, A. H., & Zhang, Y. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00822-z · Cited by 1
Waqar, M. A., Malik, A., & Mubarak, N. (2026) · Immunologic Research · doi:10.1007/s12026-026-09850-7 · Cited by 1
Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil
Hungria, V., Sureda, A. M., Campelo, G., Salvino, M. A., & Ramasamy, K. (2024) · Cancers · doi:10.3390/cancers16173063 · Cited by 1
Lung cancer immunotherapy: Status quo, problems, and prospects
Ozerskaya, I. V. O., Yusubalieva, G. M., Zhukova, O. A., Zykov, K. A., & Baklaushev, V. P. (2024) · Extreme Medicine · doi:10.47183/mes.2024-26-4-87-97 · Cited by 1
Recent Advances in CAR-T Cell Therapy: from Dual Targeting To Emerging Innovations
Saeed, H., Nesvisky, T., Kazmi, S., Huda, S., & Islam, S. (2025) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-025-00064-x · Cited by 1
Han, W., Wang, S., Zhang, M., Fu, S., Wu, W., Zhao, H., Wong, K. W., Yip, S. F., Cui, J., Chang, A. H., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04064-3 · Cited by 1
Engineering adoptive cell therapy for solid tumors
Sanjary, M., Shokati, A., Rahnama, M. A., Khaseb, S., & Ahmadvand, M. (2025) · Medical Oncology · doi:10.1007/s12032-025-03067-8 · Cited by 1
Blanquart, C., & Scherpereel, A. (2026) · Thorax · doi:10.1136/thorax-2025-223284 · Cited by 1
Hayat, M. A., Yu, S., Guo, T., Ghani, M. U., & Hu, J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117851 · Cited by 1
Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review
Abbaspour, M., Esmaeil, N., Akbari, V., Ghoreishi, M., & Rafiepoor, H. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s588323 · Cited by 1
Neurological complications of current and emerging CAR-T cell therapies
Hauswirth, A. G., & Dietrich, J. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00951 · Cited by 1
Scholler, J., Song, A., Deshmukh, M., Song, D., Gabunia, K., Ji, M., Liu, S., Fan, T., Gulendran, G., June, C. H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805950 · Cited by 1
Cancer immunotherapy: Current progress and future perspectives
Alu, A., Zhou, Y., Battaglia, G., Wei, Y., & Wei, X. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100031 · Cited by 1
Integrated Engineering of CAR ‐T Cells for Solid Tumours
Yang, C., Li, T., He, P., Zhao, Z., Li, S., & Wang, L. (2026) · Cell Proliferation · doi:10.1111/cpr.70263 · Cited by 1
Liu, Y., Li, N., Jiang, W., & Geng, Q. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.02 · Cited by 1
Ollila, H., Murumägi, A., Pellinen, T. S., Arjama, M., Sutinen, E., Volmonen, K., Haikala, H. M., Kallioniemi, O., Mäyränpää, M. I., & Ilonen, I. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.02.024 · Cited by 1
Zhang, Q., Sun, X., Hou, Y., Gao, X., Shen, K., & Qin, X. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-01981-0 · Cited by 1
The major clinical components of cancer immunotherapy (modulating cell-mediated immune mechanisms)
Bonifant, C. L., & Burns, W. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87763-3.00019-8 · Cited by 1
Driving the Immune Response Through Image-Guided Cancer Therapies
Mohanty, S., & Sheth, R. A. (2023) · Advances in Clinical Radiology · doi:10.1016/j.yacr.2023.05.003 · Cited by 1
A co-stimulatory domain increases CAR T cell therapy efficacy in mice with solid tumors
(2023) · Nature Cancer · doi:10.1038/s43018-023-00574-3 · Cited by 1
Breaks for Precision Medicine in Cancer: Development and Prospects of Spatiotemporal Transcriptomics
Yan, S., Guo, Y., Lin, L., & Zhang, W. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2023.0116 · Cited by 1
Ballesteros-Ribelles, A., Millán-López, A., Carmona-Luque, M. D., & Herrera, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115769 · Cited by 1
Frontiers and challenges of immune cell therapy research in solid tumors
Xing, X., Wang, Z., Wu, M. P., & Yao, G. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0428 · Cited by 1
da Silva, L. M. S., Gomes, E. S. D. B., Vieira, J. H., de Aguiar, M. P., Silva, S. F. M. D., & Michelin, M. A. (2024) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2024rw0935 · Cited by 1
Adoptive cell therapies in thoracic malignancies: a comprehensive review
Garitaonaindía, Y., Martínez-Cutillas, M., Uribarren, M., Redondo, I., Calvo, V., Serna‐Blasco, R., & Provencio, M. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03834-5 · Cited by 1
Recent Clinical Advancements in Immunotherapy for the Management of Breast Cancer
Upadhyay, U., Srivastava, V., Mathur, N., & Thapliyal, S. (2025) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3246 · Cited by 1
Silvestri, R., Piccardi, M., Laurenza, A., Rea, F., Sirois, A. R., Lari, M., Bartoli, F., Signore, G., Tedeschi, L., Ferraro, E., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00425 · Cited by 1
Immunotherapy in malignant pleural mesothelioma: a long story ended in success
Bongiovanni, A., Frassoldati, A., & Calabrò, L. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.78 · Cited by 1
Nutt, W. S., Kluesner, M. G., Bingham, E., Gad, E. A., Miller, D., Zepeda, V., Snyder, A. J., Marsh, S. A., Liudahl, S. M., Hoffman, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.11.693768 · Cited by 1
Barbao, P., Rodríguez-García, A., Galindo‐Albarrán, A., Giménez-Alejandre, M., Clavero, P., Lobo‐Jarne, T., Botas, M., Colell, G., Castellsagué, J., Cascalló, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.30.721530 · Cited by 1
Chen, X., Liu, J., Yang, S., Oke, A. O., Davies, S. I., Ruiz-Juarez, B., Bulliard, Y., & Nguyen, C. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-sitc2021.136
Lü, L., Lü, L., Zhang, P., Peng, Q., Liu, G., Guan, M., & Cao, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1055878/v1
Bos, S., Ricciardi, S., Caruana, E. J., Öztürk, N. A. A., Magouliotis, D. E., Pompili, C., Migliore, M., Vos, R., Meloni, F., Elia, S., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00649-2021
Immunothérapie et autres stratégies dans le traitement du mésothéliome pleural
Scherpereel, A., & Crépin, F. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00008-8
Tostivint, E. P., & Bennouna, J. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00121-5
Research Status of CAR-T Cell Immunotherapy in Tumor Treatment
Mounphoumi, S., Cao, K., Liu, G., & Fang, J. (2023) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2023.113004
Nash, A., Aghlara-Fotovat, S., Castillio, B., Hernández, A., Pugazenthi, A., Lee, H., Jang, H.-J., Nguyen, A., Lu, A., Burt, B. M., et al. (2023) · doi:10.1158/1078-0432.c.6532905.v1
Danlos, F., Texier, M., Job, B., Mouraud, S., Cassard, L., Baldini, C., Varga, A., Yurchenko, A. A., Rabeau, A., Champiat, S., et al. (2023) · doi:10.1158/2159-8290.c.6534585
Cancer-Directed Surgery for Mesothelioma
Gibney, B. C., & Detterbeck, F. C. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.02.036
Aerts, J. G. J. V., & van Meerbeeck, J. P. (2023) · European Respiratory Society eBooks · doi:10.1183/2312508x.10019722
Metadata
- Authors
- Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., Pineda, J., Perez-Johnston, R., Tan, K. S., Daly, B., Araujo Filho, J. A., Ngai, D., McGee, E., Vincent, A., Diamonte, C., Sauter, J. L., Modi, S., Sikder, D., Senechal, B., Wang, X., Travis, W. D., Gönen, M., Rudin, C. M., Brentjens, R. J., Jones, D. R., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- 6Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- 5Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
- Corresponding author
- Adusumilli, Prasad S.
- ORCID
- Adusumilli, Prasad S.
- Zauderer, Marjorie G.
- Rivière, Isabelle
- Solomon, Stephen B.
- Rusch, Valerie W.
- O'Cearbhaill, Roisin E.
- Cheema, Waseem
- Chintala, Navin K.
- Pineda, John
- Perez-Johnston, Rocio
- Tan, Kay See
- Daly, Bobby
- Sauter, Jennifer L.
- Modi, Shanu
- Wang, Xiuyan
- Travis, William D.
- Gönen, Mithat
- Rudin, Charles M.
- Brentjens, Renier J.
- Jones, David R.
- Sadelain, Michel
- Venue
- Cancer Discovery
- Published
- 2021-07-15
- Volume
- 11
- Issue
- 11
- Pages
- 2748-2763
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8563385
- OpenAlex
- W3179214161
- Cited by
- 605
- References
- 37
- Citations by year
- 2026: 124 · 2025: 119 · 2024: 131 · 2023: 125 · 2022: 90 · 2021: 15
- FWCI
- 32.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (P30 CA008748, R01 CA236615-01, R01 CA235667)
- U.S. Department of Defense (BC132124, LC160212, CA180889)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- mesothelin, chimeric antigen receptor T cells, CAR T-cell therapy, malignant pleural mesothelioma, malignant pleural effusion, pembrolizumab, anti-PD-1 therapy, intrapleural administration, combination immunotherapy, autologous T cells, safety and tolerability, overall survival
- MeSH terms
- Mesothelin, Humans, Mesothelioma, Pleural Diseases, Immunotherapy, Adoptive, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
